Kindlin‐1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types

• Paula Azorin,
• Florian Bonin,
• Zakia Tariq,
• Ambre Petitalot,
• Florence Coussy,
• Elisabetta Marangoni,
• Veronique Becette,
• Yves Denoux,
• Anne Vincent‐Salomon,
• Christophe Le Tourneau,
• Linda Larbi Cherif,
• Jerzy Klijanienko,
• Maud Kamal,
• Ivan Bièche,
• Rosette Lidereau,
• Keltouma Driouch

Affiliations

Paula Azorin

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Florian Bonin

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Zakia Tariq

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Ambre Petitalot

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Florence Coussy

Department of Medical Oncology Institut Curie Paris France

Elisabetta Marangoni

Translational Research Institut Curie, PSL Research University Paris France

Veronique Becette

Pathology Department Institut Curie Paris France

Yves Denoux

Pathology Department Foch Hospital Suresnes France

Anne Vincent‐Salomon

Pathology Department Institut Curie Paris France

Christophe Le Tourneau

Department of Drug Development and Innovation (D3i) Institut Curie Paris‐Saclay University Paris & Saint Cloud France

Linda Larbi Cherif

Department of Drug Development and Innovation (D3i) Institut Curie Paris‐Saclay University Paris & Saint Cloud France

Jerzy Klijanienko

Pathology Department Institut Curie Paris France

Maud Kamal

Department of Drug Development and Innovation (D3i) Institut Curie Paris‐Saclay University Paris & Saint Cloud France

Ivan Bièche

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Rosette Lidereau

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France

Keltouma Driouch

Pharmacogenomics Unit, Genetics Department Institut Curie Paris France